Ladenburg lowered the firm’s price target on Sonoma Pharmaceuticals to $1.50 from $3.25 and keeps a Buy rating on the shares following the fiscal 2024 report. With traction from the products launched during 2024, as well as the potential for new product launches or expansions, the firm anticipates ongoing revenue growth, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNOA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue